9:19AM Alkermes prices secondary offering of 21 mln ordinary shares held by Elan (ELN) at a price to the public of $16.50/share (ALKS) 17.30 :
Recent ALKS News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/23/2026 12:08:26 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/23/2026 12:04:37 AM
- Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] • Edgar (US Regulatory) • 05/22/2026 11:59:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2026 08:59:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2026 08:57:44 PM
- Alkermes Showcases Data From Psychiatry Portfolio and Sleep Research into Real World Patient Experience at Spring 2026 Scientific Conferences • Business Wire • 05/21/2026 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/20/2026 08:10:47 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/13/2026 09:03:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/12/2026 11:07:58 AM
- Alkermes Announces Positive Topline Results From REVITALYZ℠ Phase 3 Study Evaluating LUMRYZ® (sodium oxybate) Extended-Release in Adults With Idiopathic Hypersomnia • Business Wire • 05/12/2026 11:00:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/05/2026 08:30:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/05/2026 11:05:17 AM
- Alkermes plc Reports First Quarter 2026 Financial Results • Business Wire • 05/05/2026 11:00:00 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/04/2026 08:30:48 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/02/2026 01:05:20 AM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 05/01/2026 08:51:50 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/01/2026 08:22:08 PM
- Alkermes to Report First Quarter Financial Results on May 5, 2026 • Business Wire • 04/21/2026 08:05:00 PM
- Alkermes to Present Additional Data From Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at the American Academy of Neurology (AAN) 2026 Annual Meeting • Business Wire • 04/16/2026 11:00:00 AM
- Findings From Long-Term Analysis of the Effects of LYBALVI® (olanzapine and samidorphan) on Negative Symptoms of Schizophrenia Published in The Journal of Clinical Psychiatry • Business Wire • 04/14/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/06/2026 11:56:39 PM

